Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meta-Hydroxyephedrine
- Development stage
- Unknown
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
meta-Hydroxyephedrine (HED), also known as N-methyl-metaraminol or 11C-meta-hydroxyephedrine when radiolabeled, is a small molecule catecholamine analog and structural analog of norepinephrine. It is primarily used as a radiotracer in positron emission tomography (PET) imaging to assess sympathetic nervous system function, especially cardiac sympathetic innervation. HED is rapidly transported into sympathetic neurons by the norepinephrine transporter (NET) and stored in vesicles. Its uptake and retention are highly specific to presynaptic sympathetic nerve terminals, making it a quantitative marker for NET density and synaptic norepinephrine levels. HED is resistant to metabolism by monoamine oxidase (MAO) and catechol-O-methyltransferase. It has been investigated for use in heart failure, myocardial ischemia, arrhythmias, sleep apnea syndromes, and localization of endocrine tumors[3][5][6][7][8].
- Other names
- N-methyl-metaraminol
02
Targets
VMAT2 (Vesicular monoamine transporter 2)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on meta-Hydroxyephedrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meta-Hydroxyephedrine.